Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau, Asher Chanan‐Khan, Andrew W. Roberts, et al.
Blood (2017) Vol. 130, Iss. 22, pp. 2392-2400
Open Access | Times Cited: 254

Showing 1-25 of 254 citing articles:

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei, Pau Montesinos, Vladimir Ivanov, et al.
Blood (2020) Vol. 135, Iss. 24, pp. 2137-2145
Open Access | Times Cited: 601
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei, Stephen A. Strickland, Jing-Zhou Hou, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 15, pp. 1277-1284
Open Access | Times Cited: 583
Targeting BCL-2 regulated apoptosis in cancer
Kirsteen J. Campbell, Stephen W. G. Tait
Open Biology (2018) Vol. 8, Iss. 5, pp. 180002-180002
Open Access | Times Cited: 476
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto, et al.
Blood (2017) Vol. 130, Iss. 22, pp. 2401-2409
Open Access | Times Cited: 458
Small molecules, big impact: 20 years of targeted therapy in oncology
Philippe L. Bédard, David M. Hyman, Matthew S. Davids, et al.
The Lancet (2020) Vol. 395, Iss. 10229, pp. 1078-1088
Closed Access | Times Cited: 449
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Shaji Kumar, Simon J. Harrison, Michèle Cavo, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 12, pp. 1630-1642
Closed Access | Times Cited: 335
The proteasome and proteasome inhibitors in multiple myeloma
Sara Gandolfi, Jacob P. Laubach, Teru Hideshima, et al.
Cancer and Metastasis Reviews (2017) Vol. 36, Iss. 4, pp. 561-584
Closed Access | Times Cited: 294
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Delphine Mérino, Gemma L. Kelly, Guillaume Lessène, et al.
Cancer Cell (2018) Vol. 34, Iss. 6, pp. 879-891
Open Access | Times Cited: 264
The multiple myelomas — current concepts in cytogenetic classification and therapy
Shaji Kumar, S. Vincent Rajkumar
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 7, pp. 409-421
Closed Access | Times Cited: 253
BCL-2 as therapeutic target for hematological malignancies
Guilherme Fleury Perini, Glaciano Ribeiro, Jorge Vaz Pinto Neto, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 184
Toward personalized treatment in multiple myeloma based on molecular characteristics
Charlotte Pawlyn, Faith E. Davies
Blood (2018) Vol. 133, Iss. 7, pp. 660-675
Open Access | Times Cited: 177
BCL2 and MCL1 inhibitors for hematologic malignancies
Andrew W. Roberts, Andrew H. Wei, David C.S. Huang
Blood (2021) Vol. 138, Iss. 13, pp. 1120-1136
Open Access | Times Cited: 142
The rise of apoptosis: targeting apoptosis in hematologic malignancies
Rebecca Valentin, Stephanie Grabow, Matthew S. Davids
Blood (2018) Vol. 132, Iss. 12, pp. 1248-1264
Open Access | Times Cited: 137
Relapsed refractory multiple myeloma: a comprehensive overview
Abdul Hamid Bazarbachi, Rama Al Hamed, Florent Malard, et al.
Leukemia (2019) Vol. 33, Iss. 10, pp. 2343-2357
Closed Access | Times Cited: 133
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Nizar J. Bahlis, Heather J. Sutherland, Darrell White, et al.
Blood (2018) Vol. 132, Iss. 24, pp. 2546-2554
Open Access | Times Cited: 128
Targeting Bcl-2 for the treatment of multiple myeloma
Cyrille Touzeau, Paulo Maciag, Martine Amiot, et al.
Leukemia (2018) Vol. 32, Iss. 9, pp. 1899-1907
Closed Access | Times Cited: 124
Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer
Simona D’Aguanno, Donatella Del Bufalo
Cells (2020) Vol. 9, Iss. 5, pp. 1287-1287
Open Access | Times Cited: 122
Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax
Joel D. Leverson, Deepak Sampath, Andrew J. Souers, et al.
Cancer Discovery (2017) Vol. 7, Iss. 12, pp. 1376-1393
Open Access | Times Cited: 121
Multiple myeloma: the (r)evolution of current therapy and a glance into future
Annamaria Gullà, Kenneth C. Anderson
Haematologica (2020) Vol. 105, Iss. 10, pp. 2358-2367
Open Access | Times Cited: 113
Targeting cancer stem cells and their niche: perspectives for future therapeutic targets and strategies
Yue Zhao, Qiongzhu Dong, Jiahui Li, et al.
Seminars in Cancer Biology (2018) Vol. 53, pp. 139-155
Open Access | Times Cited: 107
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
Rachel Thijssen, Sarah T. Diepstraten, Donia M. Moujalled, et al.
Blood (2021) Vol. 137, Iss. 20, pp. 2721-2735
Open Access | Times Cited: 100
Therapeutic development and current uses of BCL-2 inhibition
Andrew W. Roberts
Hematology (2020) Vol. 2020, Iss. 1, pp. 1-9
Open Access | Times Cited: 99
Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade
Frederick J. Kohlhapp, Dipica Haribhai, Rebecca Mathew, et al.
Cancer Discovery (2020) Vol. 11, Iss. 1, pp. 68-79
Open Access | Times Cited: 98
The safety of bortezomib for the treatment of multiple myeloma
Güldane Cengiz Seval, Meral Beksaç
Expert Opinion on Drug Safety (2018) Vol. 17, Iss. 9, pp. 953-962
Closed Access | Times Cited: 91
Prognostic and predictive biomarker developments in multiple myeloma
Craig T. Wallington‐Beddoe, Rachel L. Mynott
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 91
Page 1 - Next Page

Scroll to top